Patents Assigned to Terns, Inc.
  • Thyroid hormone receptor beta agonist compounds
    Patent number: 11203587
    Abstract: Provided herein are compounds, preferably thyroid hormone receptor beta (THR beta) agonist compounds, compositions thereof, methods of their preparation, and methods of agonizing THR beta and methods for treating disorders mediated by THR beta.
    Type: Grant
    Filed: October 10, 2019
    Date of Patent: December 21, 2021
    Assignee: TERNS, INC.
    Inventors: Thorsten A. Kirschberg, Randall Halcomb, Yingzi Xu, F. Anthony Romero
  • THR? receptor agonist compound and preparation method and use thereof
    Patent number: 11084802
    Abstract: The present invention discloses a compound represented by the following Formula (I) and a pharmaceutically acceptable salt thereof. The compound improves the THR? selectivity while maintaining good THR? agonistic activity, thereby improving properties of the finished drug.
    Type: Grant
    Filed: December 12, 2019
    Date of Patent: August 10, 2021
    Assignee: TERNS, INC.
    Inventors: Shanghai Yu, Ben Li
  • THRB receptor agonist compound and preparation method and use thereof
    Patent number: 11034676
    Abstract: The present invention discloses a compound represented by the following Formula (I) and a pharmaceutically acceptable salt thereof. The compound improves the THR? selectivity while maintaining good THR? agonistic activity, thereby improving properties of the finished drug.
    Type: Grant
    Filed: September 4, 2020
    Date of Patent: June 15, 2021
    Assignee: TERNS, INC.
    Inventors: Shanghai Yu, Ben Li
  • Tricyclic ASK1 inhibitors
    Patent number: 10919911
    Abstract: Provided herein are compounds, preferably ASK1 inhibitor compounds, compositions thereof, and methods of their preparation, and methods of inhibiting ASK1 and methods for treating disorders mediated by ASK1.
    Type: Grant
    Filed: April 12, 2019
    Date of Patent: February 16, 2021
    Assignee: TERNS, INC.
    Inventors: Yingzi Xu, Randall Halcomb, Thorsten A. Kirschberg, F. Anthony Romero
  • Substituted benzoimidazoles and imidazo[4,5-c]pyridines for treating certain leukemias
    Patent number: 10889571
    Abstract: Provided herein are compounds of formula (I) or formula (Ia) that inhibit tyrosine kinase enzymatic activity of a protein selected from Abelson protein (ABL1), Abelson-related protein (ABL2), or a chimeric protein BCR-ABL1, compositions thereof, and methods of their preparation, and methods of inhibiting tyrosine kinase enzymatic activity of a protein selected from Abelson protein (ABL1), Abelson-related protein (ABL2), or a chimeric protein BCR-ABL1, and methods for treating diseases wherein modulation of BCR-ABL1 activity prevents, inhibits, or ameliorates the pathology and/or symptomology of the disease.
    Type: Grant
    Filed: September 17, 2019
    Date of Patent: January 12, 2021
    Assignee: Terns, Inc.
    Inventors: F. Anthony Romero, Thorsten A. Kirschberg, Randall Halcomb, Yingzi Xu
  • Thyroid hormone receptor beta agonist compounds
    Patent number: 10800767
    Abstract: Provided herein are compounds, preferably thyroid hormone receptor beta (THR beta) agonist compounds, compositions thereof, and methods of their preparation, and methods of agonizing THR beta and methods for treating disorders mediated by THR beta.
    Type: Grant
    Filed: August 23, 2019
    Date of Patent: October 13, 2020
    Assignee: Terns, Inc.
    Inventors: Thorsten A. Kirschberg, Randall Halcomb, Yingzi Xu, F. Anthony Romero
  • COMPOUNDS FOR TREATING CERTAIN LEUKEMIAS
    Publication number: 20200087283
    Abstract: Provided herein are compounds, preferably compounds inhibiting tyrosine kinase enzymatic activity of a protein selected from Abelson protein (ABL1), Abelson-related protein (ABL2), or a chimeric protein BCR-ABL1, compositions thereof, and methods of their preparation, and methods of inhibiting tyrosine kinase enzymatic activity of a protein selected from Abelson protein (ABL1), Abelson-related protein (ABL2), or a chimeric protein BCR-ABL1, and methods for treating diseases wherein modulation of BCR-ABL1 activity prevents, inhibits, or ameliorates the pathology and/or symptomology of the disease.
    Type: Application
    Filed: September 17, 2019
    Publication date: March 19, 2020
    Applicant: Terns, Inc.
    Inventors: F. Anthony ROMERO, Thorsten A. KIRSCHBERG, Randall HALCOMB, Yingzi XU
  • TRICYCLIC ASK1 INHIBITORS
    Publication number: 20190315767
    Abstract: Provided herein are compounds, preferably ASK1 inhibitor compounds, compositions thereof, and methods of their preparation, and methods of inhibiting ASK1 and methods for treating disorders mediated by ASK1.
    Type: Application
    Filed: April 12, 2019
    Publication date: October 17, 2019
    Applicant: Terns, Inc.
    Inventors: Yingzi XU, Randall HALCOMB, Thorsten A. KIRSCHBERG, F. Anthony ROMERO